FDA Advisory Panel Votes to Recommend Compounding of BPC-157, TB-500 and Four Other Peptides, Rejects Emideltide

The U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) met July 23-24, 2026 at the agency's White Oak campus and voted, substance by substance, on whether seven peptides should be added to the Section 503A bulk drug substances list, which governs the ingredients traditional compounding pharmacies may legally use. The 14-member committee recommended six of the seven peptides for inclusion and voted against the seventh, overriding written objections from the FDA's own career review staff on every substance under consideration, according to coverage of the meeting by STAT, Medical Daily and Pharmaceutical Executive. Peptide Science Daily previously reported on the meeting's scheduling and on the staff review documents that preceded it.

On July 23, the committee voted 8-6, with one abstention, to recommend BPC-157 for ulcerative colitis, KPV for wound treatment and inflammatory conditions, and TB-500 for wound healing. MOTS-c, evaluated for obesity and osteoporosis, passed on a narrower 7-5 vote with two abstentions, Pharmaceutical Executive reported. Medical Daily described the BPC-157 tally as prompting an audible reaction in the meeting room when it was announced.

On July 24 the committee took up three additional peptides. It voted 7-4 to recommend epitalon for insomnia and 8-5 to recommend semax for migraine and the neurological conditions cerebral ischemia and trigeminal neuralgia, STAT reported. Emideltide, also known as delta sleep-inducing peptide or DSIP, was the only substance the committee declined to recommend, failing on a 6-7 vote after panelist David Pope, chief pharmacy officer at XiFin Pharmacy Solution, switched his vote after having supported the earlier peptides. Pope said he was concerned about emideltide's "potentially dangerous downstream consequences," according to STAT.

The votes came despite FDA staff review documents, reported ahead of the meeting, that found insufficient human evidence to support any of the seven substances. During public comment on BPC-157, Nina Zeldes of Public Citizen's Health Research Group said the peptide's purported benefits are "largely based on anecdotal evidence" and that interest in it "appears to be driven by those who stand to benefit from increased demand," Medical Daily reported.

The committee's makeup drew its own scrutiny. Pharmaceutical Executive, citing Reuters, reported that eight of the panel's 14 members were recently appointed under Health and Human Services Secretary Robert F. Kennedy Jr. and that six of those new appointees operate or work for clinics that offer peptide treatments.

The committee's recommendations are advisory and non-binding, and none of the seven peptides is an FDA-approved drug regardless of the outcome. "There are three distinct legal events the market keeps treating as one, removal from Category 2, a PCAC recommendation, and actual placement on the Category 1 compoundable list following notice-and-comment rulemaking," said Dustin Robinson, a founding partner at LumaLex Law, quoted in Pharmaceutical Executive. Robinson said the rulemaking cycle that would follow a favorable FDA decision "realistically runs eight to twelve months" before 503A pharmacies would have clear legal authority to compound the substances, and the FDA has departed from advisory committee recommendations before.

As of publication, the FDA had not announced a final decision on any of the seven peptides. BPC-157, TB-500, MOTS-c, KPV, semax, epitalon and DSIP remain outside FDA-approved use, and compounded preparations are not reviewed by the FDA for safety, effectiveness or manufacturing quality before reaching patients. This report describes regulatory status only and does not offer medical or dosing guidance.